Carbonyl substituted diazaspiro compounds and its use

Inventors

Hu, Taishan • Huang, Bryan • Shen, Quanrong • Li, Honghai • MA, Xiaochu

Assignees

Servier Pharmaceuticals LLC

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12760021-B2

Patent

Publication Date

2026-10-13

Expiration Date


Abstract

A compound of formula I, in which the variables are as defined in the specification; pharmaceutical compositions containing them, methods for preparing them, and their use.

Core Innovation

The invention comprises carbonyl-substituted diazaspiro compounds of formula I, including stereoisomers, racemates, tautomers, hydrates, solvates, and pharmaceutically acceptable salts thereof. The structures define alternatives for core atoms X, Y, and Z, substituents R1 through R5, and structural parameters a, b, c, d, n, and m. Disclosed embodiments incorporate substituted diazaspiro[3.5]nonane-pyrimidine or 1,2,4-triazine scaffolds, heteroaryl-aryloxy benzamide structures, and nitrogen-containing heterocyclyl rings.

The compounds function as inhibitors of the interaction between menin and MLL or MLL-fusion proteins for preventing or treating cancer or diabetes. Reported screening results demonstrate menin-MLL1 biochemical inhibition and antiproliferative activity across MLL-fusion or NPM1-mutant leukemia cell lines. Disclosed examples also exhibit improved human liver microsome half-lives and reduced hERG inhibition relative to SNDX-5613.

The disclosure further encompasses pharmaceutical compositions, therapeutic combinations with anti-neoplastic agents, and methods of treating cancer or diabetes. These therapeutic approaches relate directly to inhibiting interactions between menin and MLL or MLL fusion proteins across hematologic and solid tumor indications. Because the background section is omitted, the underlying technical problem being solved is not explicitly described in the patent text.

Claims Coverage

The patent claims identify one independent claim, claim 1, which defines two inventive features directed to compounds of formula I and their specified forms.

Compound of formula I

Claim 1 covers a compound of formula I defining alternatives for core atoms X, Y, and Z; substituents R1, R2, R3, R4, and R5; and structural parameters a, b, c, d, n, and m, encompassing substituted heteroaryl, aryl, and nitrogen-containing heterocyclyl groups.

Specified forms and salts of formula I

Claim 1 further encompasses a stereoisomer, racemate, tautomer, hydrate, solvate, or pharmaceutically acceptable salt of the compound of formula I.

The independent claim defines a structural genus of formula I compounds and associated stereoisomer, racemate, tautomer, hydrate, solvate, and salt forms. Dependent claims extend coverage to specific analog selections, pharmaceutical compositions, combinations with anti-neoplastic agents, inhibition of menin-MLL interactions, and methods of treating cancer or diabetes.

Stated Advantages

Selected compounds show improved human liver microsome half-lives compared with SNDX-5613.

Several selected compounds show reduced hERG inhibition compared with SNDX-5613.

Reported compounds show menin-MLL1 inhibition and antiproliferative activity across leukemia cell lines.

Documented Applications

Inhibiting the interaction of menin with MLL and/or MLL fusion proteins.

Prevention or treatment of cancer, including hematologic and solid tumors, such as acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and MLL-rearranged leukemias.

Prevention or treatment of diabetes.

Use in pharmaceutical compositions and therapeutic combinations comprising the disclosed compounds with anti-neoplastic agents.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.